Phathom Pharmaceuticals, Inc.
PHATNasdaqCIK 1783183HealthcareFiscal year ends Dec 31
Reports and events: 155 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2907:05 ET | 10-Q | Quarterly reportPeriod 2026-09-30 | 0001193125-26-436961 |
| 2026-10-2907:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-436959 |
| 2026-10-2606:02 ET | 8-K | 8.01 Other events | 0001193125-26-430977 |
| 2026-10-2317:00 ET | 8-K | 8.01 Other events | 0001193125-26-430621 |
| 2026-09-2916:45 ET | 8-K | 8.01 Other events | 0001193125-26-407696 |
| 2026-07-3007:05 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-324867 |
| 2026-07-3007:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-324865 |
| 2026-06-2308:00 ET | 8-K | 8.01 Other events | 0001193125-26-278533 |
| 2026-05-2116:01 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-234379 |
| 2026-04-3007:05 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-193946 |
| 2026-04-3007:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-193945 |
| 2026-04-0708:00 ET | DEF 14A | Proxy statementPeriod 2026-05-19 | 0001193125-26-144570 |
| 2026-02-2607:06 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-073379 |
| 2026-02-2607:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-073377 |
| 2026-01-0816:03 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-007660 |
| 2026-01-0716:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-006266 |
| 2025-11-0417:24 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001231919-25-000418 |
| 2025-11-0407:05 ET | 8-K | 8.01 Other events | 0001193125-25-263534 |
| 2025-10-3007:05 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-257390 |
| 2025-10-3007:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-257382 |
| 2025-10-2706:02 ET | 8-K | 8.01 Other events | 0001193125-25-250611 |
| 2025-10-0608:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-230984 |
| 2025-08-2017:18 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001415889-25-022496 |
| 2025-08-0707:05 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-104548 |
| 2025-08-0707:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-174943 |
| 2025-06-1608:05 ET | 8-K | 8.01 Other events | 0001193125-25-141119 |
| 2025-06-0916:01 ET | 8-K | 5.07 Shareholder vote results | 0001193125-25-137800 |
| 2025-06-0616:23 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-137094 |
| 2025-05-1316:22 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001415889-25-012779 |
| 2025-05-0107:05 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-061440 |
| 2025-05-0107:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-108726 |
| 2025-04-2316:03 ET | DEF 14A | Proxy statementPeriod 2025-06-03 | 0000950170-25-057326 |
| 2025-04-1608:06 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-082089 |
| 2025-04-0108:17 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-069748 |
| 2025-03-0608:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-047882 |
| 2025-03-0608:05 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-034183 |
| 2024-12-1108:05 ET | 8-K | 8.01 Other events | 0001193125-24-274876 |
| 2024-11-0716:05 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-123264 |
| 2024-11-0708:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-252642 |
| 2024-08-2216:05 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-24-205352 |
| 2024-08-1917:13 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-202879 |
| 2024-08-0816:05 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-093885 |
| 2024-08-0808:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-196506 |
| 2024-07-1808:05 ET | 8-K | 8.01 Other events | 0001193125-24-180750 |
| 2024-06-1416:05 ET | 10-K/A | Annual report, amendedPeriod 2023-12-31 | 0000950170-24-073629 |
| 2024-06-1416:05 ET | 10-Q/A | Quarterly report, amendedPeriod 2024-03-31 | 0000950170-24-073628 |
| 2024-06-0613:59 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-24-155898 |
| 2024-05-2416:03 ET | 8-K | 5.07 Shareholder vote results; 8.01 Other events | 0001193125-24-147017 |
| 2024-05-0916:06 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-056888 |
| 2024-05-0908:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-134793 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 29, 2026, 07:19 ET. Listed shows no prices and gives no investment advice.